IRF5 and lung carcinoma: Collectively, these findings conclusively demonstrate that IRF5 M1‐exos possess inhibitory effects on lung cancer cell survival and proliferation while attenuating cellular migration and invasion capabilities, thereby impeding tumorigenesis.